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Feline panleukopenia
Canine parvovirus type 2 (CPV-2), which is closely related to feline pan-
leukopenia virus (FPV), was described in 1978 as a new parvovirus
(cited in Carmichael1). it evolved from FPV with the acquisition of five
or six amino acid changes in the capsid protein2 and does not infect cats.
However, during further adaptation to the dog, which most likely
occurred in the raccoon, the virus underwent
amino acid changes that made the mutated
virus bind more efficiently to the canine
cellular receptor, while retaining the abil-
ity to infect cats.3,4 This led to the emer-
gence of the new type, CPV-2a, which
contains a series of further mutations
including those at amino acid 426 of
the VP2 that determine the antigenic
types 2a, 2b and 2c. The parvo viruses
currently circulating in dog populations
worldwide (genetically and antigenically
defined as types CPV-2a, -2b and -2c) can
infect cats and may even cause disease.5–7
However, CPV infections of cats are rare in Europe
and the USA, and the virus has only sporadically been found in diag-
nostic material.6 CPV was isolated from feline peripheral blood lympho-
cytes after numerous blind passages, and viral dNA was demonstrated
subsequently by PCR.8 Recently, however, a case of CPV-2c infection in
a cat with severe clinical disease was described in Portugal.9
during the evolution of FPV to CPV-2 with its various antigenic
types, neutralising epitopes have become modified such that cross-
neutralisation by FPV antisera is markedly lower against the newer
viruses.10
Persistent infections with viral shedding are rare; using PCR, healthy
cats have been found positive for FPV in faeces over weeks,11 and CPV-
2 viruses could be isolated from the faeces of healthy cats in the UK in
two shelters.12 it is unknown whether these findings are of epidemio-
logical significance.
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Overview: The ABCD has published 34 guidelines
in two Special Issues of the Journal of Feline
Medicine and Surgery (JFMS): the first in July 2009
(Volume 11, Issue 7, pages 527–620) and the second
in July 2013 (Volume 15, Issue 7, pages 528–652).
The present article contains updates and new
information on 18 of these (17 disease guidelines
and one special article ‘Prevention of infectious
diseases in cat shelters’). For detailed information,
readers are referred to the guidelines published 
in the above-mentioned JFMS Special Issues.
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The feline panleukopenia guidelines
that the present article is updating were
published in J Feline Med Surg in 2009 
(11: 538–546) and updated in 2013 (15:
530–531). This further update has been
compiled by Uwe Truyen.
European Advisory Board on Cat Diseases
The European Advisory Board on Cat Diseases (ABCD) 
is a body of experts in immunology, vaccinology 
and clinical feline medicine that issues guidelines on
prevention and management of feline infectious diseases
in Europe, for the benefit of the health and welfare of cats.
The guidelines are based on current scientific knowledge
of the diseases and available vaccines concerned.
The latest full versions of the disease guidelines
updated in this article are available at 
www.abcdcatsvets.org and www.abcd-vets.org
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The parvovirus sequences encountered in
wild carnivores (pumas, coyotes, raccoons,
and others) revealed a wide genotypic varia-
tion. This finding suggests infection of preda-
tors by their parvovirus-infected prey, and
hence a new route of infection.13
Following intrauterine infection, FPV antigen
persists in the cerebellum of kittens for weeks.14
detailed information on the prevention and
management of parvovirus infection in cats 
is provided in the ABCd guidelines15 and a 
previous update.16
Feline herpesvirus infection
Feline herpesvirus (FHV), together with feline
calicivirus, is involved in the feline upper 
respiratory tract syndrome. in addition,
FHV has been recognised as the most
important cause of corneal ulcera-
tion, both superficial and deep, and
in particular of dendritic ulcers.
The infection becomes latent,
allowing lifelong persistence of the
virus, which is sporadically inter-
rupted by episodes of viral reacti-
vation and re-excretion. Thiry et al17
and Horzinek et al16 presented a table
summarising recommendations for
treatment of acute FHV ocular disease.
The amino acid L-lysine has been proposed
for systemic treatment, to be administered as 
a bolus, separate from food. No reports of side
effects have been published, but findings on
efficacy are conflicting.18–25 Cave et al26 inves-
tigated the effects of physiological concentra-
tions of L-lysine on the in vitro replication of
FHV at L-arginine levels sufficient to maintain
cell growth. FHV was not inhibited at any L-
lysine concentration studied. The in vivo effi-
cacy of L-lysine treatment on primary and
recurrent FHV infection is unknown.
Feline leukaemia virus infection
Feline leukaemia virus (FeLV) is a gamma
retrovirus affecting domestic cats worldwide.
it also infects small wild cats including Felis
silvestris, European and iberian lynxes,
Florida panthers and the Chilean wildcat
(Leopardus guigna).27–30 The prevalence of
FeLV infection in Europe and North
America has greatly diminished. in indi-
vidually kept cats it is low; often, but
not everywhere, less than 1%.31–35
After infection of bone marrow cells,
viraemia develops within a few weeks.
Mainly lymphocytes and monocytes are
infected, whereas later infection involves
mostly neutrophils.36 Viraemia may be
overcome by the immune system (transient
viraemia) in some cats,37 whereas others
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develop a persistent viraemia. A smaller pro-
portion (~5%) exhibits an atypical course of
infection, displaying antigenaemia, but no or
only low-level viraemia.38,39 A cat that has
overcome viraemia remains latently infected.
Reactivation may occur; it is not clear how
often this happens under field conditions, but
it is believed to be rare. Generally, up to 10% of
all feline blood samples submitted to a labora-
tory prove to be provirus-positive and p27-
negative; since FeLV may be reactivated in
some of these cats, they should be considered
latently infected.35,40,41 Probably no cat can
clear an FeLV infection from all cells.
Experimentally, susceptible kittens can be
protected from FeLV infection after passive
immunisation with high-titred specific anti -
sera.38 This observation suggests that antibod-
ies have a role in protection; however, once
persistent viraemia has become established,
treatment with neutralising monoclonal anti-
bodies to FeLV has proven ineffective.42
in an experimental study, seroconversion
was observed in cats as the sole evidence of
FeLV infection.43 These cats had been exposed
once intranasally to low doses of FeLV (10,000
FFU). Since some of them seroconverted, it
was concluded that the virus had replicated
somewhere to sufficient levels to trigger anti-
body synthesis. PCR analysis of several
organs was negative, indicating that further
replication must have been controlled by the
immune system. 
in most situations, individual cats are tested
for FeLV infection. However, when the cost of
testing is a limitation, pooled saliva samples
can be used to detect FeLV RNA; the RNA
PCR is sufficiently sensitive to detect a single
infected cat in a pool of up to 30 samples. This
approach may be chosen when screening 
multi-cat households.44 While all viraemic cats
are positive for FeLV RNA in saliva, a few
may shed FeLV RNA in saliva, but are not
(yet) viraemic or antigenaemic.45
The observation that antibodies can develop
as the sole parameter of exposure to FeLV43 led
to the examination of various FeLV antigens to
assess their diagnostic potential to detect anti-
bodies. in contrast to published results,46 a
recombinant preparation of FeLV p15(E) proved
highly effective for the detection of antibodies
induced by FeLV infection and thus for the
diagnosis of a previous infection.47
The HiV integrase inhibitor raltegravir
was found to inhibit FeLV replication in
vitro.48 The drug is tolerated well by cats,
and within 1 week leads to a marked reduc-
tion in viral loads. However, this is not suf-
ficient for the immune system to control the
viraemia, and treatment must be continued
over long periods in order to maintain low viral




on prevention and management
The feline herpesvirus infection
guidelines that the present article is
updating were published in J Feline Med
Surg in 2009 (11: 547–555) and updated in
2013 (15: 531–533). This further update has
been compiled by Etienne Thiry.
Feline leukaemia
virus infection: 
ABCD guidelines on prevention
and management
The feline leukaemia virus infection
guidelines that the present article is
updating were published in J Feline Med
Surg in 2009 (11: 565–574) and updated in
2013 (15: 534–535). This further update has
been compiled by Hans Lutz.
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and observed for clinical signs. After quaran-
tine, they can be introduced into small groups
of healthy cats. FeLV antigen- and/or FiV
antibody-positive cats should be kept sepa-
rate, but may be housed together with other
retrovirus-positive cats, and adopted out to
suitable homes as soon as possible. 
The ABCd does not recommend euthanasia
of healthy FeLV-positive cats. However, if no
adequate home can be found, if separation
from the rest of the population is impossible,
or if the cat is sick, euthanasia should be con-
sidered. detailed recommendations are pro-
vided in the ABCd guidelines ‘Prevention of
infectious diseases in cat shelters’.53
detailed information on the prevention and
management of feline leukaemia virus infec-




it is generally accepted that feline immuno -
deficiency virus (FiV) infection can induce
clinical signs of immunodeficiency, leading to
opportunistic infections or lymphomas, and
clinical signs consistent with immunodefi-
ciency in natural infection have been docu-
mented.55 However, in some cats the clinical
signs are mild, which likely reflects both het-
erogeneity among circulating field isolates as
well as host factors, and it has been reported
that many FiV-infected cats have a normal life
expectancy.56–58 Therefore, surrogate markers
are required to provide an objective assess-
ment of FiV progression in individual cats.
Recently it was shown that viruses dominat-
ing in early infection display a distinct recep-
tor usage phenotype and that the emergence
of viruses with an altered receptor usage phe-
notype coincides with the onset of immuno -
deficiency.59 Accordingly, viral phenotyping
might assist in the clinical staging of individ-
ual cats diagnosed with FiV infection.
FiV infection was found to be prevalent in a
survey of four large-scale hoarding situa-
tions;60 this high prevalence was probably
related to the fact that the cats were living in
close confinement under stressful condi-
tions, and exhibiting aggressive
behaviour. Therefore, it is recom-
mended that cats should be tested
for FiV infection at the time of
seizure during hoarding investi-
gations, as the results will influ-
ence housing decisions, medical
care and adoption options.  
FiV infection is also common in
rescue shelters and it is recom-
mended that all cats in rescue cen-
tres should be neutered and kept
in many experiments it was shown that no
FeLV vaccine provides complete protection or
prevents infection. Cats that overcome p27
antigenaemia without exception test provirus-
positive in blood, and also test positive for
viral RNA in plasma, although at much lower
levels than persistently viraemic cats [EBM
grade iii].50 These experiments confirm that
FeLV vaccination does not induce sterilising
immunity and does not protect cats from
infection. However, cats vaccinated with 
conventional, adjuvanted, whole inactivated
virus vaccines did not show p27, viral RNA or
dNA after a low-dose challenge with the sub-
group A virus FeLV A/61E.51 Various factors
may have played a role: the challenge virus
was used at a very low dose (10,000 TCid50
injected once, intraperitoneally), the assays
used were less sensitive than those used by
Hofmann-Lehmann et al,50 and the cats had a
different genetic background. Testing for
FeLV in internal organs would have resulted
in observations as reported by Major et al.43
Thus, the proposition remains valid that 
vaccination against FeLV protects cats from
disease but not from infection. 
Until recently, no data had been published to
demonstrate that immunity lasts longer than 
1 year after primary vaccination; most vaccine
manufacturers therefore recommend annual
boosters. However, the demonstration that one
FeLV vaccine provided immunity for at least 
2 years52 [EBM grade ii] suggests that this may
also apply to other vaccines. Combined with
the lower susceptibility of adult cats to FeLV
infection, the ABCd recommends that, in cats
older than 3 years, a booster immunisation
every 2–3 years is sufficient.
Wherever possible, cats entering a shelter
should be kept in quarantine for at least 
3 weeks, if not (re)homed sooner. All incom-
ing cats (at least in shelters that allow contact
between cats after the quarantine period)
should be screened for FeLV antigen and
feline immunodeficiency virus (FiV) antibody,
and ideally also for FeLV antibody.47 Antigen-
negative  but antibody-positive results sug-
gest that the cat is not viraemic/antigenaemic,
but may be latently infected. Therefore, PCR
for FeLV dNA should additionally be per-
formed. if the PCR shows a high FeLV dNA
load, this cat should prudently be considered
latently infected; the cat should best be placed
in a home without other cats for several
months. if only an FeLV antigen test is per-
formed, cats testing negative should ideally
be retested 6 weeks later (and kept in quaran-
tine for this time period), as it may take 4–6
weeks after infection for the test to return pos-
itive results. To prevent (re)activation of other
infections caused by the stress of entering the




ABCD guidelines on prevention
and management
The feline immunodeficiency virus
infection guidelines that the present article
is updating were published in J Feline Med
Surg in 2009 (11: 575–584) and updated in
2013 (15: 535). This further update has been
compiled by Margaret J Hosie.
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indoors, in order to reduce the risk of territori-
al aggression, which can result in penetrating
bite wounds and consequently FiV transmis-
sion. This recommendation is supported by
studies linking cat bite wounds and abscesses
with FiV infection.61,62 A recent survey of cats
in a rescue shelter, in which FiV-infected cats
were housed together with uninfected cats,
found no evidence of FiV transmission, in
spite of the cats having un restricted access,
and sharing food and water bowls, litter trays
and bedding for several years.63 However, it is
possibly significant that the cats had been
neutered before entering this shelter and the
median age of the uninfected cats was 4
months; kittens are a low risk group for FiV
infection64 because territorial aggression has
not yet developed.  Similarly, neutered cats are
less likely to display territorial aggression
than intact cats and, therefore, FiV transmis-
sion might be more likely to occur in rescue
centres housing older cats, especially if those
cats exhibit aggressive behaviour. 
detailed information on the prevention and
management of feline immunodeficiency
virus infection is provided in the ABCd
guidelines65 and a previous update.16
Rabies
Rabies is caused by a Lyssavirus, a member 
of the Rhabdoviridae family. The genus
Lyssavirus contains 12 species: rabies
virus, Mokola virus, Lagos bat virus
and duvenhage virus from Africa,
European bat lyssaviruses (EBLV) 1
and 2, Australian bat lyssavirus,
and five recently recognised species
(international Committee on
Taxonomy of Viruses, 2012). Each of
these viruses is considered capable of
causing a rabies-like disease in animals
and humans.
Various control measures (eg, vaccination of
wildlife, immunisation of dogs and cats, diag-
nostic measures, control of pet movements)
eliminated rabies from large regions of
Europe, especially its western and northern
parts. in rabies-free countries, however,
though sporadic, the illegal importation of
pets from regions where this disease is endem-
ic poses an increasing risk.66 Rabies was
recently recognised in a kitten imported into
France from Morocco,67 and a few cases in
dogs were documented in Europe recently.
As a result of the mass vaccination of dogs
in many areas affected by wildlife rabies, cats
have become the companion animal species
most commonly reported as rabid, as is the
case in many states of the USA.68 in a recent
report from Pennsylvania, among 2755 rabid
animals with reported human exposure, as
many as 799 (29.0%) were free-ranging cats,
whereas only 57 (2.1%) were dogs.69
Because of the public health risk associated
with susceptible domestic cats becoming
infected following exposure to rabid wild or
domestic animals, all cats with outdoor access
in endemic areas should be vaccinated. The
vaccine should be administered in accordance
with local or state regulations. in countries
where rabies is absent, rabies vaccination is
indicated when a cat moves or travels to an
area where rabies is endemic.
EU Regulation 576/2013 established new
rules for the non-commercial movement of pet
animals (dogs, cats and ferrets) between EU
countries as of 29 december 2014. According
to these rules, all such cats should be identi-
fied by microchip (or tattoo, if applied before
4 July 2011) and vaccinated against rabies; 
a 21-day waiting period following primary
vaccination is required. This means that for
the purpose of travel, cats generally must be at
least 15 weeks old, as 12 weeks is the mini-
mum age for rabies vaccination. Some coun-
tries accept younger animals without rabies
vaccination under certain conditions, but most
do not (for details see http://ec.europa.eu/
food/animal/liveanimals/pets/nat_rules_
dogscatferret_en.htm). According to the recent
pet movement regulation, serological testing
for rabies neutralising antibodies is no longer
required before entry into any EU member
state.
detailed information on the prevention and
management of rabies in cats is provided in the
ABCd guidelines70 and a previous update.16
Feline infectious peritonitis
Given the number of major recent develop-
ments in the field of feline coronavirus (FCoV)
and feline infectious peritonitis (FiP), fully
updated ABCd guidelines on FiP will be 
published in the near future. For the purpose
of this interim update, some key develop-
ments in FiP diagnosis and treatment are out-
lined below.
Among the most interesting of the develop-
ments relating to FiP diagnosis is the advent
of a commercially available reverse tran-
scription PCR (RT-PCR) test which 
distinguishes mutations on the spike
of type i FCoVs that are associated
with the development of systemic
spread of the virus.71 There is a
question of this test not being as
sensitive as conventional FCoV
RT-PCR, not only because it does
not detect type ii FCoVs, but also
because the spike protein is the 
protein most subject to evolutionary




The feline rabies guidelines that the
present article is updating were
published in J Feline Med Surg in 2009 (11:
585–593) and updated in 2013 (15:
535–536). This further update has been
compiled by Tadeusz Frymus.
Feline infectious
peritonitis: ABCD
guidelines on prevention 
and management
The feline infectious peritonitis guidelines
that the present article is updating were
published in J Feline Med Surg in 2009 (11:
594–604) and updated in 2013 (15: 536). 
This further update has been compiled by
Diane Addie.
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is the most variable of the coronavirus genes,
and thus primers may not bind, giving a false
negative result.
it is the view of the ABCd that RT-PCR is 
a preferred method of FiP confirmation for
effusions, over immunofluorescence of
macrophages, which is less widely available
and more prone to human error.
in a comparison of commercially available
FCoV antibody tests, 16 applications of FCoV
antibody tests were considered: sensitivity
was deemed extremely important because
many uses of FCoV antibody tests involve 
ruling out a diagnosis of FiP or FCoV infec-
tion.72 An in-house ELiSA fared best, both in
terms of sensitivity/specificity and quantity
of sample required (only 5 µl). The most sen-
sitive rapid immunomigration (RiM) tests
were identified.  RiM tests fared best in terms
of rapidity of result, which is useful when
screening a healthy cat, but they may give
false negative results if used to support FiP
diagnosis on effusion samples, due to binding
of virus to antibody, rendering the antibody
unavailable for the test antigen.73
For treatment, Polyprenyl immuno -
stimulant (Sass & Sass) is only for use in non-
effusive FiP, having no efficacy in effusive FiP.
one study of three non-effusive FiP cases
reported survival of 14 months for one cat and
over 2 years for two cats [EBM grade iV].74
However, a conference abstract report of 58
cats showed only 22% survival at 6 months,
with just one cat surviving at a year [EBM
grade iii].75 A placebo-controlled study is
required.
Gil et al76 showed that in cats with FeLV or
FiV infection, feline interferon omega therapy
resulted in a tendency towards reduced FCoV
shedding [EBM grade iii]. 
Chloroquine inhibits FCoV replication in
vitro and has anti-inflammatory effects in
vivo.77 However, reported survival times were
only around 30 days at best and the drug
increased alanine aminotransferase levels.
Thus, the ABCd does not recommend its use
until further studies have demonstrated sig-
nificant benefit.
A placebo-controlled double blind trial on
propentofylline showed no efficacy [EBM
grade i].78
detailed information on the prevention and
management of feline infectious peritonitis 
is provided in the ABCd guidelines79 and a
previous update.16
Influenza A virus infection 
in cats
Recommendations for the preven-
tion of influenza A H5N1 and
H1N1 infections in cats were pub-
lished in the ABCd guidelines80
and subsequently updated.16
Cats were recently found to be
susceptible to the H3N2 and H5N2
influenza viruses, the agents of
canine influenza in Asia, leading to
morbidity and mortality in cats for
H3N2, but only to mild clinical signs for
H5N2.81,82 Experimental infection of cats with
the recent H5N8 influenza A virus was suc-
cessful, but remained subclinical.83
Feline viral papillomatosis 
Papillomaviruses cause cutaneous lesions in
man and several animal species, including
cats. The ABCd has published guidelines on
the prevention and management of feline
viral papillomatosis.84
in each host, including cats,85 different
papillomavirus (PV) types exist. To date, four
feline PVs from domestic cats have been fully
sequenced and classified.85
These viruses were desig-













infection in cats: 
ABCD guidelines on 
prevention and management
The influenza A virus infection in cats
guidelines that the present article is
updating were published in J Feline Med
Surg in 2009 (11: 615–618) and updated in
2013 (15: 537). This further update has been
compiled by Etienne Thiry.
Feline viral
papillomatosis: 
ABCD guidelines on prevention
and management
The feline viral papillomatosis guidelines
that the present article is updating were
published in J Feline Med Surg in 2013 (15:
560–562). This update has been compiled
by Herman Egberink.
Evidence-based medicine (EBM) is a process of clinical decision-making 
that allows clinicians to find, appraise and integrate the current best 
evidence with individual clinical expertise, client wishes and patient needs. 
This article uses EBM ranking to grade the level of evidence of various state-
ments and recommendations on a scale of I to IV as follows: 
< EBM grade I This is the best evidence, comprising data obtained from
properly designed, randomised controlled clinical trials in the target
species (in this context cats);
< EBM grade II Data obtained from properly designed, randomised
controlled studies in the target species with spontaneous disease in 
an experimental setting;
< EBM grade III Data based on non-randomised clinical trials, multiple
case series, other experimental studies, and dramatic results from
uncontrolled studies;
< EBM grade IV Expert opinion, case reports, studies in other species,
pathophysiological justification. 
Further reading
Lloret A. The process of evidence-based medicine. J Feline Med Surg 2009; 11: 529.
Roudebush P, Allen TA, Dodd CE, et al. Application of evidence-based medicine to
veterinary clinical nutrition. J Am Vet Med Assoc 2004; 224: 1765–1771.
EBM ranking used in th is  ar t ic le
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was reported; dNA was detected in all 20
Bowenoid in situ carcinomas (BiSCs) exam-
ined, and in 17 of 20 cases of invasive SCC.87
However, FdPV-2 dNA was also present in
52% of normal skin swabs.88 Although FdPV-2
has been detected most frequently in BiSCs
and SCCs, other PV types have also been iden-
tified. Recently, a novel PV type, designated
FcaPV-3, was detected in a feline BiSC.86 in one
study, 50% of the sequenced PV dNA was
most closely related to human PV dNA.89 in
another study, PV dNA could not be detected
in any of 30 oral SCC samples screened,90
which is at variance with earlier observations. 
Bartonella species infection 
in cats
The ABCd guidelines on Bartonella
species infection in cats91 list various
species and subspecies of Bartonella
that are confirmed or potential
human pathogens: B bacilliformis, 
B quintana, B elizabethae, B grahamii, 
B henselae, B clarridgeiae, B koehlerae,
B vinsonii subspecies berkhoffii, 
B vinsonii subspecies arupensis, 
B washoensis and B asiatica. Additionally
B rochalimae should now be included, for
which reservoir hosts may be raccoons, coy-
otes, red foxes and cats. The vectors are fleas,
and humans may be accidental hosts.
The important role of fleas in the transmis-
sion of B henselae and B clarridgeiae among cats
has been demonstrated. Using a quantitative
molecular approach, B henselae dNA was
detected in both fleas and their faeces for the
entire life span of the arthropod (ie, 12 days)
starting from 24 h after the blood meal.92
Recently, the possible role of several bat fly
species (Nycteribiidae) as Bartonella vectors has
been studied. it remains a subject of debate,
but a reservoir function should be considered
in addition to pathogenic, parasitic or mutual-
istic interactions.93
The role of Bartonella as a pathogen after
natural transmission is still unclear; however,
B henselae was found in association with pyo-
granulomatous myocarditis and diaphrag-
matic myositis in two cats.94
For laboratory diagnosis, a real-time PCR
and pyrosequencing-based algorithm was
described that allowed rapid differentiation of
at least 11 medically relevant Bartonella species
within 5 h from receipt of the specimens.95
Coxiellosis/Q fever in cats
Q fever is a zoonotic disease caused by Coxiella
burnetii. ABCd guidelines on prevention and
management of coxiellosis/Q fever in cats
have been published.96
Farm animals and







lence as high as
61.5% was recent-
ly demonstrated.97
A Q fever out-
break among veteri-
nary hospital personnel
was linked to a caesarean section on a parturi-
ent queen. The breeding queen was C burnetii
seropositive, and antibodies were demonstrat-
ed in 26% of the cats living in the same
cattery.98
Francisella tularensis infection 
in cats
Tularaemia is a potentially fatal zoonosis.
Various clinical syndromes occur, but most
patients either present with a localised infec-
tion of the skin and draining lymph nodes
(ulceroglandular form) or with a systemic
infection (typhoidal tularaemia). oro pharyn -
geal and pneumonic forms are rare. 
The risk of acquiring the infection from cats
is low, but exists for owners of cats with out-
door access, as well as for veterinarians and
technicians.99 Regular parasiticidal treatment
to prevent tick infestations is recommended
for outdoor cats. When handling animals with
suppurative or draining skin or lymph
node lesions in endemic areas, gloves
and goggles should be worn. Gloves
should be also be worn when exam-
ining the oral mucosa. Handling of
diagnostic samples by laboratory
staff requires adherence to appro-
priate biosafety procedures.100
detailed information on the 
prevention and management of
tularaemia in cats is provided in the
ABCd guidelines.101
Mycobacterioses in cats
in recent years, awareness of the importance of
mycobacterial infections in humans and ani-
mals has been increasing. ABCd guidelines on
the prevention and management of mycobac-
teriosis in cats were published in 2013.102
An unsual cluster of Mycobacterium bovis infec-
tion in cats was recently reported from the UK.
Cat-to-cat transmission was suspected, and two
humans became infected.103 Also nosocomial
infection was reported in a cluster of cases that
had attended a veterinary practice in ireland.104
Bartonella
species infection in
cats: ABCD guidelines on
prevention and management
The Bartonella species infection in
cats guidelines that the present article is
updating were published in J Feline Med
Surg in 2013 (15: 563–569). This update has
been compiled by Fulvio Marsilio.
Coxiellosis/Q fever
in cats: ABCD guidelines
on prevention and
management
The coxiellosis/Q fever in cats
guidelines that the present article is
updating were published in J Feline Med
Surg in 2013 (15: 573–575). This update
has been compiled by Herman Egberink.
Francisella
tularensis infection in
cats: ABCD guidelines on
prevention and management
The Francisella tularensis infection in
cats guidelines that the present article is
updating were published in J Feline Med
Surg in 2013 (15: 585–587). This update has
been compiled by Maria Grazia Pennisi.
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For diagnostic purposes, PCR is recom-
mended; it should ideally be performed on
fresh tissue samples, but fixed stained smears
and formalin-fixed paraffin-embedded tissues
can be used with good sensitivity.105
The zoonotic risk has to be considered when
planning therapeutic measures.102 it is compli-
cated by the fact that confirmation of the
mycobacterial species takes time, and antibiot-
ic therapy requires several months. Therefore,
euthanasia rather than treatment should be
considered as a sensible course of action, in
view of the public health implications and the
prognostic uncertainties of treatment.
For the tuberculosis complex and non-tuber-
culous mycobacteria (NTM) groups, double or
triple therapy is currently recommended:
rifampicin (10–15 mg/kg q24h), plus a
quinolone (marbofloxacin [2 mg/kg q24h] or
pradofloxacin [3–5 mg/kg q24h]), plus a
macrolide (clarithromycin [125 mg/cat q24h
or 7–15 mg/kg q24h] or azythromycin [5–15
mg/kg q24h]) for 6–9 months. ideally, the
three drugs should be administered during an
initial phase of 2 months, followed by two of
the drugs for 4–7 months [EBM grade iii].106,107
The newer fluoroquinolones (moxifloxacin
and pradofloxacin) might be more effective
than the older ones.108,109 Unpublished clinical
experience suggests that pradofloxacin is a
good choice; in localised disease, pradofloxacin
would be a good initial treatment pending
species confirmation [EBM grade iV].110
Treatment of NTM infections is ideally based
on culture and susceptibility tests for each case,
as different mycobacterial species or strains may
have different antibiotic sensitivity. However,
this is not always possible, as specific culture
systems are unavailable or results take too long.
disseminated M avium-intracellulare complex
(MAC) infections usually respond poorly to
treatment, and older generation quinolones are
not very effective.111–113 The recommended first
choice treatment is clarithromycin with clofaz-
imine (4–8 mg/kg q24h) or rifampicin or doxy-
cycline (5–10 mg/kg q12h) based on the few
cases reported with good outcomes [EBM
grade iV].114–116 Limited clinical experience with
pradofloxacin suggests that it is more effective
than the older fluoroquinolones.110
Most cats with feline leprosy can be
cured by surgery (small lesions), 
and treatment with combinations 
of rifampicin, clofazimine, clar-
ithromycin and pradofloxacin for
several months [EBM grade
iV].117,118 Spontaneous remission
has been documented in one cat.119
Keeping the cat indoors and
avoiding contact with wild rodents
are the only measures for preventing
mycobacterial infection. 
Euthanasia or treatment of cats with con-
firmed M bovis infection should be a consen-
sus decision between the owner and the
veterinarian, but due to the risk of cat-to-
human transmission (see box above) and
antimicrobial resistance, euthanasia has been




sia might be considered after infection with
any of the other potentially zoonotic species
(M tuberculosis, M microti and M avium).
Cryptococcosis in cats
Feline cryptococcosis occurs rarely or spo-
radically, but Cryptococcus gattii has a
worldwide distribution with a high
prevalence along the Pacific coast of
North America. it has been report-
ed also from Brazil,121 and in
Europe from Austria, denmark,
France, Germany, Greece, italy, 
the Netherlands, Portugal, Spain,
Sweden and the United King -
dom.122 C neoformans var grubii also
has a worldwide distribution and is
commonly isolated from affected 
individuals of various animal species. 
C neoformans is considered a cosmopolitan
oppor tunistic pathogen in human urban pop-
ulations, whereas C gattii is a true pathogen,
more prevalent in rural areas.123
Feline cryptococcosis caused by C neofor-
mans or C gattii is clinically indistinguishable.
This disease can manifest after a long incu-
bation period124 and presents in different clin-
ical forms, including the nasal form, central
nervous system (CNS) form (which can derive
from the nasal form or occur independently),
the cutaneous form and the systemic form.125
CNS involvement most likely arises following
local dissemination through the cribriform
plate.126 Recently, otitis interna following sys-
temic spread of the fungus was reported.127
detailed information on the prevention and
management of cryptococcosis in cats is 
provided in the ABCd guidelines.125
Mycobacterioses in
cats: ABCD guidelines on
prevention and management
The mycobacterioses in cats
guidelines that the present article is
updating were published in J Feline Med
Surg in 2013 (15: 591–597). This update has
been compiled by Albert Lloret.
Cryptococcosis in
cats: ABCD guidelines on
prevention and management
The cryptococcosis in cats guidelines
that the present article is updating were
published in J Feline Med Surg in 2013 (15:
611–618). This update has been compiled
by Maria Grazia Pennisi.
Po t e n t i a l  z o o n o t i c  r i s k
All members of the TB complex are potentially zoonotic, including M microti.
However, the risk of transmission from cats (and dogs) to humans is low, as
cats are spillover hosts.107,120 In a recent cluster of feline cases of M bovis
infection in the south west of England, two people became infected after
having been in contact with the cats.103 The Public Health Agency in England
then changed the risk level of transmission from negligible to low
(www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317140243205).
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Sporotrichosis in cats
Sporotrichosis is a deep cutaneous
mycosis caused by the dimorphic
saprophytic fungus Sporothrix
schenckii. S schenckii is not a unique
species but a complex containing
at least four distinct species. Most
feline cases reported from Brazil
are caused by S brasiliensis.128
The prevalence of the disease
varies markedly between regions. in
Central and South America, it represents
the most common deep mycosis. in Brazil it
is endemic, and an important epidemic affect-
ing humans, cats and dogs was reported in 
Rio de Janeiro.129–131 More than 2000 feline
cases over 7 years have been seen by just one
institution, showing the magnitude of the epi-
demics and the challenges of disease control.132
Using histopathology and staining proce-
dures, the organisms are readily visualised.
Cats with few and well organised granulomas
tend to have low numbers of fungal organisms
in the lesions. Cats in poor general condition
and with large numbers of granulomas have
the greatest numbers of fungal organisms.133
detailed information on the prevention and
management of sporotrichosis in cats is 
provided in the ABCd guidelines.134
Toxoplasma gondii infection 
in cats
Several antibody tests have been used to
detect infection with Toxoplasma gondii and to
diagnose toxoplasmosis in cats. The indirect
immunofluorescence assay can be adapted to
detect immunoglobulin M (igM), igG and igA
antibodies. 
Antibody test results from healthy cats are
useful to assess the health risk for humans. An
antibody-negative cat could be shedding
oocysts (early after infection, before antibodies
have developed) or will shed oocysts if exposed;
this cat poses the greatest public health risk. 
An antibody-positive cat is unlikely to shed
oocysts, because antibodies need 2–3 weeks to
develop, by which time the infection
has been controlled; also, 
shedding usually occurs
only once in the cat’s life-
time. Furthermore, a cat
with antibodies is
unlikely to shed oocysts
if re-exposed or
immuno suppressed.135
in one study, cats inocu-
lated with T gondii tis sue
cysts were orally re-chal-
lenged several years later,
and a few of them did shed
oocysts after this second challenge (although
only low amounts and over a short time).136
This, however, has never been shown to occur
in naturally infected cats. Thus, the risk of shed-
ding by an antibody-positive cat is very low.
Antibodies are common in both healthy and
diseased cats and, therefore, do not prove clini-
cal toxoplasmosis. Not only igG antibodies, but
also antibodies of the igM class are commonly
detected in healthy cats and stay high over long
periods; thus their detection is also of no use 
for diagnosing toxoplasmosis. T gondii-specific
igM is detected in the serum of cats with latent
or reactivated infection and titres, therefore, do
not indicate recent exposure. if increasing igM
titres are detected, however, this can raise the
suspicion of clinical toxoplasmosis.
Clinical toxoplasmosis is ideally diagnosed
by detection of the organism in muscle biop-
sies or bronchoalveolar lavage fluid, or by PCR
performed on cerebrospinal fluid (CSF) or
aqueous humour. during acute illness, tachy-
zoites can be detected in tissues and body 
fluids by cytology. They are rarely found in
blood, but occasionally in CSF, fine-needle
aspirates of organs (eg, lymph nodes), and
transtracheal or bronchoalveolar washings,
and are common in the peritoneal and thoracic
fluid of animals developing thoracic effusions
or ascites. detection of tachyzoites confirms
the diagnosis.
A tentative diagnosis can be based on
increasing igM titres, exclusion of other caus-
es of the clinical signs, and a positive clinical
response to an anti-Toxoplasma drug.135,137
detailed information on the prevention and
management of T gondii infection in cats is
provided in the ABCd guidelines.138
Leishmaniosis in cats
Leishmania infection is less well known in cats
than in dogs, but it may be underestimated 
in endemic areas and is of zoonotic concern.
detailed information on the prevention and
management of leishmaniosis in cats was
published in the ABCd guidelines.139
The information available for treatment is
based only on case reports. despite
clinical improvements following
long term oral administra-
tion of allopurinol (10–20
mg/kg q12h or q24h), the
infection is not cleared,
and recurrence of clini-
cal signs may occur
after cessation of thera-
py, as in dogs [EBM
grade iV].140,141 Meg -
lumine antimoniate (5–50
mg/kg or 375 mg/cat q24h
SC/iM under different proto-
Toxoplasma gondii
infection in cats: 
ABCD guidelines on 
prevention and management
The Toxoplasma gondii infection in cats
guidelines that the present article is
updating were published in J Feline Med
Surg in 2013 (15: 631–637). This update
has been compiled by Katrin Hartmann.
Leishmaniosis in
cats: ABCD guidelines on
prevention and management
The leishmaniosis infection in cats
guidelines that the present article is
updating were published in J Feline Med
Surg in 2013 (15: 638–642). This update has
been compiled by Maria Grazia Pennisi.
Sporotrichosis in
cats: ABCD guidelines on
prevention and management
The sporotrichosis in cats guidelines
that the present article is updating were
published in J Feline Med Surg in 2013 (15:
619–623). This update has been compiled
by Albert Lloret.
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In shelter situations, infectious diseases are difficult to prevent and
they spread quickly.53 In addition, shelters are unstable biological
environments; not only are disease outbreaks frequent, but also new
pathogens may emerge or virulent variants of endemic pathogens
may arise as a result of rapid transmission cycles and forced agent
evolution. The virulent systemic feline calicivirus infection is a point
in case.152
The ABCD guidelines describe the most important fac-
tors in minimising the spread of infectious agents in the
shelter environment.53 These include: housing in
individual sections (quarantine pens for incoming
cats, isolation facilities for sick or potentially
infectious cats, separate accommodation for
clinically healthy, FIV- and FeLV-negative cats,
and for pregnant and lactating queens and their
kittens); testing for infectious agents; hygiene
measures; and stress reduction. Stress is reduced
above all by allowing for low animal densities, and
by providing adequate bedding and environmental
enrichment such as scratching posts, toys and hiding
areas. Newly sheltered cats provided with a hiding box during quar-
antine had significantly lower stress levels compared with cats with-
out this enrichment.153 Animal handling (eg, stroking anxious cats)
may have positive effects, as suggested by an increase in secretory
IgA and reduced incidence of upper respiratory tract disease.154
Synthetic pheromones have been used in shelters with the objec-
tive of reducing stress. They are expected to alter the emotion-
al state of the cat via the limbic system and the
hypothalamus, and have been recommended for the
management of anxiety-related behaviours, such
as house soiling.155 Horwitz and Pike156 have 
published anecdotal observations that synthetic
pheromones are useful when introducing new
cats into a household. These data have not
been corroborated by impartial, controlled 
studies. However, based on reports about use of
synthetic pheromones in the treatment of 
undesirable, stress-related behaviour, they may be
considered in addition to other stress-reducing
measures.
Prevention of
infectious diseases in cat
shelters: ABCD guidelines
The prevention of infectious diseases
in cat shelters guidelines  that the
present article is updating were published
in J Feline Med Surg in 2013 (15: 546–554).
This update has been compiled by 
Karin Möstl.
cols) was used for therapy in four cases and led
to good clinical responses, but long term follow-
up is lacking [EBM grade iV].140
Giardiasis in cats
Giardia is a protozoan parasite of the small
intestine. Seven genotypes have been identi-
fied and designated A to G. Types F and G are
the subgroups commonly seen in cats, where-
as A and B occur mainly in man and are con-
sidered as potentially zoonotic.142 Giardiasis 
in cats is not considered a zoonotic risk.143,144
However, recent European studies demon-
strated the presence of
subgroup A in
cats,145–147 either
alone or as a dual
infection (A and
F).146 Genotype
B has also been
identified in






score, presence of diarrhoea
and infection with G intestinalis has been
observed;149 but, in other studies, agent pres-
ence has not been notably different in cats with
diarrhoea as compared with healthy cats. Co-
infections with other enteropathogens have
been demonstrated to be frequent in the UK.150
detailed information on the prevention and
management of giardiasis in cats is provided




The giardiasis in cats guidelines that
the present article is updating were
published in J Feline Med Surg in 2013 (15:
650–652). This update has been compiled
by Corine Boucraut-Baralon.
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